QC
JAZZ icon

Quantessence Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Quantessence Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,609
Closed -$212K – 92
2025
Q3 		$212K Buy
+1,609
New +$193K 0.07% 159
2025
Q1 		– Sell
-2,357
Closed -$290K – 405
2024
Q4 		$290K Buy
+2,357
New +$278K 0.12% 173

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Quantessence Capital's JAZZ Position: Q4 2025 in Review

Quantessence Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 1,609 shares — an estimated $212K sold.

Quantessence Capital first reported a position in JAZZ in Q4 2024 and held it in 2 quarters. The position peaked at $290K in Q4 2024. 573 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Quantessence Capital reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Quantessence Capital sold 1,609 Jazz Pharmaceuticals shares in Q4 2025, an estimated $212K.
  • Quantessence Capital first reported a position in Jazz Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Quantessence Capital's Jazz Pharmaceuticals position peaked at $290K in Q4 2024.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Quantessence Capital's 13F filing for Q4 2025, filed 17 Feb 2026.